Sanofi Consumer Healthcare India Ltd (NSE: SANOFICONR, BSE: 544250) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹8,163 Cr, it ranks #657 by market cap among the 6,197 Indian listed companies on FinBizNet, and #13 of 63 in Pharmaceuticals. At ₹3,629.00 (as of 16 Nov 2026), the share price is 30.9% below its 52-week high of ₹5,255.00 and 14.5% above its 52-week low of ₹3,168.20. The share price is down 22.3% over one year and down 19.3% over three months.
| Current Price | ₹3,629.00 |
|---|---|
| Market Cap | ₹8,163 Cr |
| NSE Symbol | SANOFICONR |
| BSE Code | 544250 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 34 |
| Return on Equity | 73.09% |
| Return on Assets | 37.99% |
| 52-Week Range | ₹3,168.20 – ₹5,255.00 |
| 1-Year Price Change | -22.3% |
| 3-Month Price Change | -19.3% |
| Beta (1Y) | 0.25 |
| Dividend Yield | 2.12% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.sanofi.com/en/Consumer-Healthcare/health-and-well-being |
| Revenue | ₹263 Cr |
|---|---|
| Net Profit | ₹77 Cr |
| Net Margin | 29.1% |
| EPS (Basic) | ₹33.26 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sanofi Consumer Healthcare India Ltd reported revenue of ₹263 Cr in Q2 FY27, up 12.5% from ₹234 Cr in Q2 FY26 and up 11.6% from ₹236 Cr in Q1 FY27. It posted a net profit of ₹77 Cr for the quarter, against a net profit of ₹63 Cr in Q2 FY26 (up 21.8%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹173 Cr (Q4 FY25) to ₹263 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹263 Cr | ₹77 Cr | 29.1% |
| Q1 FY27 | ₹236 Cr | ₹69 Cr | 29.2% |
| Q4 FY26 | ₹229 Cr | ₹68 Cr | 29.6% |
| Q3 FY26 | ₹251 Cr | ₹67 Cr | 26.5% |
| Q2 FY26 | ₹234 Cr | ₹63 Cr | 26.9% |
| Q1 FY26 | ₹221 Cr | ₹61 Cr | 27.5% |
| Q4 FY25 | ₹173 Cr | ₹50 Cr | 29.0% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 71.27% of Sanofi Consumer Healthcare India Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 57.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. It offers products in the allergy, physical wellness, and pain care segments under brands, such as Allegra, Combiflam, Avil, DePURA, Festal, and Novalgin NU through distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains, and e-commerce. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited is a subsidiary of Opella Healthcare Participations B.V.
1. Pharmaceutical Business-This segment engages in pharmaceutical business. 2. No Operations-NA 3. NA-NA 4. NA-NA
1. Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Sanofi Consumer Healthcare India Ltd | ₹8,163 Cr | 34 | 73.09% | ₹263 Cr | -22.3% |
Listed by market capitalisation. Ratios are shown for context only.
Sanofi Consumer Healthcare India Ltd is trading at ₹3,629.00, with a market capitalisation of ₹8,163 Cr.
Sanofi Consumer Healthcare India Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Sanofi Consumer Healthcare India Ltd has a P/E of 34 and a return on equity of 73.09%.
Sanofi Consumer Healthcare India Ltd is listed on the NSE under the symbol SANOFICONR and on the BSE under the scrip code 544250.
Sanofi Consumer Healthcare India Ltd's share price is down 22.3% over one year and down 19.3% over three months. Its 52-week range is ₹3,168.20 to ₹5,255.00.
In Q2 FY27, Sanofi Consumer Healthcare India Ltd reported revenue of ₹263 Cr and net profit of ₹77 Cr, with basic EPS of ₹33.26 (standalone, parsed from the company's exchange filing).
Sanofi Consumer Healthcare India Ltd reported revenue of ₹263 Cr in Q2 FY27, up 12.5% from ₹234 Cr in Q2 FY26 and up 11.6% from ₹236 Cr in Q1 FY27.
Promoters held 71.27% of Sanofi Consumer Healthcare India Ltd's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.